|
Market Closed -
Australian S.E.
02:14:16 2026-08-14 EDT
|
5-day change | 1st Jan Change | ||
| 136.50 AUD | -0.74% |
|
+3.26% | -20.94% |
| 08-11 | Global drugmakers invest billions to boost US presence | RE |
| 08-09 | ASX Midday Sector Update: Healthcare Stocks Advance, Financial Sector Struggles | MT |
Company Valuation: CSL Limited
Data adjusted to current consolidation scope
| Fiscal Period: June | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 97,314 | 89,299 | 89,052 | 95,184 | 76,024 | 46,343 | - | - |
| Change | - | -8.24% | -0.28% | 6.89% | -20.13% | -39.04% | - | - |
| Enterprise Value (EV) 1 | 101,307 | 88,520 | 99,731 | 105,710 | 85,005 | 55,058 | 54,320 | 53,666 |
| Change | - | -12.62% | 12.66% | 5.99% | -19.59% | -35.23% | -1.34% | -1.2% |
| P/E | 41x | 38.6x | 40.8x | 36.1x | 25.4x | -51.8x | 32.3x | 15x |
| PBR | 11.6x | 6.13x | 5.64x | 5.48x | 3.93x | 2.88x | 2.87x | 2.62x |
| PEG | - | -4.91x | -7.25x | 1.8x | 1.9x | 0x | -0x | 0x |
| Capitalization / Revenue | 9.44x | 8.45x | 6.69x | 6.43x | 4.89x | 3.01x | 2.97x | 2.87x |
| EV / Revenue | 9.83x | 8.38x | 7.49x | 7.14x | 5.46x | 3.58x | 3.48x | 3.32x |
| EV / EBITDA | 27.2x | 24.6x | 25.6x | 22.3x | 16.5x | 10.6x | 10.5x | 9.97x |
| EV / EBIT | 32.4x | 30.2x | 32.5x | 27.7x | 19x | 12.3x | 12.3x | 11.7x |
| EV / FCF | 41.8x | 57.1x | 72.6x | 55.2x | 29.1x | 20x | 18.1x | 18.5x |
| FCF Yield | 2.39% | 1.75% | 1.38% | 1.81% | 3.44% | 5.01% | 5.52% | 5.4% |
| Dividend per Share 2 | 2.22 | 2.22 | 2.36 | 2.64 | 2.92 | 2.857 | 2.925 | 3.089 |
| Rate of return | 1.04% | 1.2% | 1.28% | 1.34% | 1.86% | 2.95% | 3.02% | 3.19% |
| EPS 2 | 5.21 | 4.8 | 4.53 | 5.45 | 6.17 | -1.867 | 2.999 | 6.459 |
| Distribution rate | 42.6% | 46.3% | 52.1% | 48.4% | 47.3% | -153% | 97.5% | 47.8% |
| Net sales 1 | 10,310 | 10,562 | 13,310 | 14,800 | 15,558 | 15,380 | 15,589 | 16,173 |
| EBITDA 1 | 3,720 | 3,596 | 3,900 | 4,750 | 5,151 | 5,200 | 5,152 | 5,380 |
| EBIT 1 | 3,130 | 2,927 | 3,069 | 3,812 | 4,468 | 4,459 | 4,422 | 4,603 |
| Net income 1 | 2,375 | 2,255 | 2,194 | 2,642 | 3,002 | -966.7 | 1,185 | 3,090 |
| Net Debt 1 | 3,993 | -778.6 | 10,679 | 10,526 | 8,981 | 8,715 | 7,977 | 7,323 |
| Reference price 2 | 213.82 | 185.38 | 184.61 | 196.96 | 157.01 | 96.77 | 96.77 | 96.77 |
| Nbr of stocks (in thousands) | 455,126 | 481,706 | 482,372 | 483,253 | 484,212 | 478,912 | - | - |
| Announcement Date | 8/17/21 | 8/16/22 | 8/14/23 | 8/12/24 | 8/18/25 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -52.01x | 3.59x | 10.62x | 2.94% | 46.5B | |
| 18.66x | 4.35x | 10.25x | 0.48% | 80.48B | |
| 38.08x | 13.03x | 24.79x | -.--% | 51.06B | |
| 21.94x | 4.85x | 13.86x | 0.66% | 48.19B | |
| 37.43x | 3.46x | 13.16x | -.--% | 31.12B | |
| -7.42x | 10.33x | -6.67x | -.--% | 25.41B | |
| 53.09x | 3.4x | 26.31x | -.--% | 24.43B | |
| 70.88x | 6.81x | 45.49x | -.--% | 21.11B | |
| 23.51x | 5.06x | 13.17x | -.--% | 16.28B | |
| -29.56x | 17x | -45.32x | -.--% | 15.88B | |
| Average | 17.46x | 7.19x | 10.57x | 0.41% | 36.05B | |
| Weighted average by Cap. | 16.01x | 6.56x | 12.73x | 0.58% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- CSL Stock
- Valuation CSL Limited
Select your edition
All financial news and data tailored to specific country editions
